TABLE 2.
Cox regression model for estimates of survival free from EDSS worsening and disability progression, and NEDA‐2 survival during the whole follow‐up
| Variable | EDSS worsening | Disability progression | NEDA‐2 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Group, AHSCT | 0.96 (0.46–2.03) | 0.924 | 0.65 (0.28–1.52) | 0.320 | 0.69 (0.34–1.41) | 0.311 |
| Age at treatment, years | 1.02 (0.98–1.06) | 0.229 | 1.01 (0.97–1.06) | 0.588 | 1.02 (0.98–1.05) | 0.357 |
| SP phase duration, years | 1.01 (0.93–1.09) | 0.729 | 0.99 (0.89–1.10) | 0.848 | 0.99 (0.92–1.07) | 0.936 |
| Previous DMTs, n | 1.17 (0.91–1.50) | 0.214 | 1.23 (0.93–1.64) | 0.150 | 1.15 (0.90–1.46) | 0.265 |
Abbreviations: AHSCT, autologous haematopoietic stem cell transplantation; CI, confidence interval; DMT, disease‐modifying treatment; EDSS, Expanded Disability Status Scale; HR, hazard ratio; NEDA‐2, no evidence of disease activity 2; SP, secondary progressive.